Also of note, despite the substantial cross-talk between Estrogen Receptor (ER) signalling and the PI3K/AKT/mTOR pathway, ER status did not impact the potency of serabelisib and sapanisertib in breast and endometrial cancer cell lines. This evidence concerns the gene PIK3CG and endometrial cancer.